Show us the money: Sustainable finance tech for COP26 to think about
COP26 is likely to bring more power to the net-zero movement. But what changes can...
Analysis
Rare Diseases 2021: maintaining the human element in decentralised trials
AGTC’s director of patient enrollment discusses the importance of the human touch in decentralised rare...
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
Inside the $45bn robotics market: The taxonomy and value chain behind today’s robot helpers
The robotics industry was worth $45bn in 2020, and by 2030, it will have grown...
Waning Covid-19 vaccine efficacy: what does the data show?
While Covid-19 vaccines’ protection does appear to wane, most experts agree that universal booster rollouts...
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Sanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News team.
Covid-19 mRNA vaccines for kids likely to be safe and effective but vigilance needed
Experts point to uncharted factors in Covid-19 vaccine research in kids as mRNA jab developers reveal their authorisation plans.
Rare Diseases 2021: GlobalData’s Bonnie Bain on embracing disruption in pharma
GlobalData’s head of pharma analyses whether Covid-19 is a catalyst for lasting change in clinical research.
Tracking the pharma sector’s Covid-19 recovery: How has the sector fared in Q2 2021?
The pharma sector has emerged as a relatively strong performer in the world economy when it comes to post-pandemic perfomance in Q2 2021. Activity levels in the sector were 16.4%…
The Metaverse: Future of post-pandemic business, or just another attempt to kickstart VR/AR adoption?
Tech business leaders are talking up the metaverse. But is this anything more than yet another attempt to get us all to start using VR? Giacomo Lee finds out.
Telemedicine tech is yet to catch up to dermatology clinical trial demands
The pandemic pushed dermatologists to pivot to telemedicine, but new experience shows its full potential is yet to be realised.
